04 November 2015

A Unitary SPC… and a recalibration?

On 28 October, the European Commission presented its strategy for a ‘deeper and fairer Single Market’, containing a number of proposals intended to modernise the Single Market in a way that improves the way in which it functions and guarantees appropriate protection. The strategy contains targeted actions in three key areas:

  • Creating opportunities for consumers, professionals and businesses
  • Encouraging and enabling modernisation and innovation
  • Ensuring practical delivery that benefits consumers and businesses in their daily lives.

A section on consolidating Europe's IP framework, in particular, focuses on the Unitary Patent. As the Commission notes, the main challenge now is to 'get the endgame right', which it identifies as including addressing uncertainties as to how the Unitary Patent will work with national patents and national SPCs, and the possible creation of a unitary SPC title. A Unitary SPC would, the Commission suggests, lead to enhanced certainty for industries subject to regulated market authorisations and improve transparency and certainty for both manufacturers of novel and generic/biosimilar medicines. The Commission goes further and states that it intends to explore ‘recalibration’ of certain aspects of patent and SPC protection more generally, noting that an SPC manufacturing waiver could lead to significant new job creation in the EU and that an update of the scope of the patent research exemption would lead to a smooth supply of active pharmaceutical ingredients throughout the Single Market.

A Guide to Doing Business in China

We explore the key issues being considered by clients looking to unlock investment opportunities in the People’s Republic of China.

Doing Business in China
Share on LinkedIn Share on Facebook Share on Twitter
    You might also be interested in

    Whilst it was comforting to hear from the UK’s data protection regulator, the Information Commissioner’s Office (ICO)

    30 April 2020

    The Coronavirus Large Business Interruption Loan Scheme (CLBILS) builds upon the UK government’s financial support being extended to UK businesses during the current period of COVID-19...

    30 April 2020

    In our work with international companies supplying goods to the UK, we see a number of common issues arising regularly.

    08 November 2019

    8 questions most frequently asked by clients in relation to patent litigation in China.

    24 July 2017

    This site uses cookies to enhance your experience and to help us improve the site. Please see our Privacy Policy for further information. If you continue without changing your settings, we will assume that you are happy to receive these cookies. You can change your cookie settings at any time.

    For more information on which cookies we use then please refer to our Cookie Policy.